Heart failure & cardiomyopathies
Eligibility for Vericiguat in a Real-World, Contemporary Heart Failure Population
Authors' conclusion
In a real-world study, 9% of patients met the eligibility criteria of the VICTORIA trial, but up to 13% complied with guideline recommendations and up to 19% met FDA or EMA criteria. In Italy, drug costs would be covered by up to 10% of patients.
Study context
- Population
- Consecutive heart failure (HF) patients at an elective ambulatory visit, 5 Italian university hospitals, 3–28 July 202372% men, median age 69 years
- Participants
- 346 patients
- Outcome
- Eligibility for vericiguat by VICTORIA trial criteria, HF guideline recommendations, FDA/EMA label criteria and Italian refundability criteria
Methodological detailsmulticentre, 5 university hospitals, consecutive patients
- Multicentre
- 5 university hospitals
- Consecutive patients
Main finding
As reported in the abstract
Eligibility for vericiguat
- Met VICTORIA trial eligibility criteria
- 9%
- Met European and American HF guideline recommendations
- 13%
- Met Food and Drug Administration (FDA) label criteria
- 19%
- Met European Medicines Agency (EMA) label criteria
- 17%
- Costs covered by Italian NHS (SGLT2i not mandatory)
- 10%
- Costs covered by Italian NHS (SGLT2i requested)
- 8%
Observational data: associations, not effects.
Original publication
Eligibility for Vericiguat in a Real-World, Contemporary Heart Failure Population. ESC Heart Fail. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →